Pre treatment with aspirin made cancer stem cells sensitive to doxorubicin in breast cancer cells
Thursday, December 31, 2020
Aspirin reverse Chemotherapy drug resistance
Pre treatment with aspirin made cancer stem cells sensitive to doxorubicin in breast cancer cells
via WordPress https://ift.tt/3n1CrW7
Monday, December 21, 2020
Friday, December 11, 2020
Metabolic road map of cancer
Memorial Sloan Kettering hospital and Dana Farber institute Doctors mapped the metabolic changes in cancer cells
Metabolic road map of cancer
Memorial Sloan Kettering hospital and Dana Farber institute Doctors mapped the metabolic changes in cancer cells
via WordPress https://ift.tt/3a7TRO9
Keto or high fat diets increase cancer growth?
High fat diets impairs your CD8 t cells and increase cancer cell growth
Keto or high fat diets increase cancer growth?
High fat diets impairs your CD8 t cells and increase cancer cell growth
via WordPress https://ift.tt/3m3n4Ms
Wednesday, December 09, 2020
Melatonin for Advanced prostate cancer
Melatonin increased overall survival by more than twice of that in the placebo group
Melatonin for Advanced prostate cancer
Melatonin increased overall survival by more than twice of that in the placebo group
via WordPress https://ift.tt/3qEZKbd
Sunday, December 06, 2020
Minichromosome maintenance proteins as DNA replication brakes
MCM act as speed bumps in DNA replication esp on cancer growth
Wednesday, December 02, 2020
Sobering numbers of cancer drugs
“Less than 20% (19.3%) of cancer science discoveries touted as breakthrough, landmark, groundbreaking, or highly promising translated into clinical therapy or practice with a median follow-up of 15 years.
Among clinically adopted treatments in our analysis, most were approved based on surrogate endpoints and only 9.1% found a survival benefit. Among the eight therapies with an OS benefit, the median benefit provided was 2.8 months.
Our results suggest that claims of major discovery are associated only with modest rates of ultimate clinical success.”
Sobering numbers of cancer drugs
“Less than 20% (19.3%) of cancer science discoveries touted as breakthrough, landmark, groundbreaking, or highly promising translated into clinical therapy or practice with a median follow-up of 15 years.
Among clinically adopted treatments in our analysis, most were approved based on surrogate endpoints and only 9.1% found a survival benefit. Among the eight therapies with an OS benefit, the median benefit provided was 2.8 months.
Our results suggest that claims of major discovery are associated only with modest rates of ultimate clinical success.”
via WordPress https://ift.tt/37pz9pP
Subscribe to:
Posts (Atom)